HK1127618A1 - Compounds for proteasome enzyme inhibition - Google Patents
Compounds for proteasome enzyme inhibitionInfo
- Publication number
- HK1127618A1 HK1127618A1 HK09107615.1A HK09107615A HK1127618A1 HK 1127618 A1 HK1127618 A1 HK 1127618A1 HK 09107615 A HK09107615 A HK 09107615A HK 1127618 A1 HK1127618 A1 HK 1127618A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- enzyme inhibition
- proteasome enzyme
- proteasome
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56988504P | 2004-05-10 | 2004-05-10 | |
US61004004P | 2004-09-14 | 2004-09-14 | |
US63436604P | 2004-12-07 | 2004-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1127618A1 true HK1127618A1 (en) | 2009-10-02 |
Family
ID=34967797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09107615.1A HK1127618A1 (en) | 2004-05-10 | 2007-09-07 | Compounds for proteasome enzyme inhibition |
Country Status (18)
Country | Link |
---|---|
US (3) | US8088741B2 (de) |
EP (3) | EP2564834A3 (de) |
JP (3) | JP5108509B2 (de) |
CN (2) | CN102875642A (de) |
AU (1) | AU2005243168B2 (de) |
BR (1) | BRPI0510802A (de) |
CA (1) | CA2565407A1 (de) |
CY (1) | CY1115605T1 (de) |
DK (1) | DK2030981T3 (de) |
ES (1) | ES2510840T3 (de) |
HK (1) | HK1127618A1 (de) |
IL (4) | IL179020A (de) |
PL (1) | PL2030981T3 (de) |
PT (1) | PT2030981E (de) |
RU (1) | RU2384585C2 (de) |
SG (1) | SG185963A1 (de) |
SI (1) | SI2030981T1 (de) |
WO (1) | WO2005111008A2 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1745064T3 (pl) | 2004-04-15 | 2011-06-30 | Onyx Therapeutics Inc | Związki do hamowania enzymu proteazomu |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
CA2565407A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Compounds for enzyme inhibition |
PT2260835E (pt) * | 2004-12-07 | 2013-05-28 | Onyx Therapeutics Inc | Composição para inibição do proteassoma |
CN105237621A (zh) | 2005-11-09 | 2016-01-13 | 欧尼斯治疗公司 | 用于酶抑制的化合物 |
MX2008016512A (es) | 2006-06-19 | 2009-02-26 | Proteolix Inc | Epoxicetonas peptidicas para la inhibicion del proteasoma. |
WO2008140782A2 (en) * | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
BRPI0816807A2 (pt) * | 2007-09-12 | 2017-05-16 | Dr Reddy's Laboratories Inc | bortezomib e processo para a produção do mesmo |
CL2008002966A1 (es) | 2007-10-04 | 2010-06-25 | Onyx Therapeutics Inc | Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros. |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
CN107266482A (zh) | 2008-06-17 | 2017-10-20 | 米伦纽姆医药公司 | 硼酸酯化合物及其医药组合物 |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
EP3021120A1 (de) | 2009-02-20 | 2016-05-18 | Michael P. Lisanti | Verfahren zur diagnose oder prognose eines neoplasmas einschliesslich der bestimmung des expressionsgrads eines proteins in stromazellen neben dem neoplasma |
AR075899A1 (es) * | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
EA201290844A1 (ru) | 2010-03-01 | 2013-03-29 | Оникс Терапьютикс, Инк. | Соединения для ингибирования иммунопротеасом |
KR20130094185A (ko) | 2010-04-07 | 2013-08-23 | 오닉스 세라퓨틱스, 인크. | 결정성 펩티드 에폭시케톤 면역프로테아좀 저해제 |
CN102212036B (zh) * | 2011-04-08 | 2012-10-17 | 苏州二叶制药有限公司 | N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法 |
JP6251176B2 (ja) | 2011-10-28 | 2017-12-20 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Nae阻害物質に対する応答のバイオマーカー |
EP2776586B1 (de) | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarker der reaktion auf proteasomenhemmer |
CA2855356A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
WO2013112601A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
US10085987B2 (en) | 2012-01-27 | 2018-10-02 | Thomas Jefferson University | MCT protein inhibitor-related prognostic and therapeutic methods |
US9751957B2 (en) | 2012-02-15 | 2017-09-05 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
JP6176259B2 (ja) * | 2012-06-29 | 2017-08-09 | 日産化学工業株式会社 | 立体選択的なエポキシケトン化合物の製造方法 |
EP2869820A4 (de) * | 2012-07-09 | 2016-02-17 | Onyx Therapeutics Inc | Prodrugs von peptidepoxidketonproteaseinhibitoren |
CN103570806B (zh) * | 2012-07-26 | 2020-04-07 | 圣特莱国际公司 | 多肽环氧酮化合物 |
WO2014018807A1 (en) * | 2012-07-26 | 2014-01-30 | Centrax International, Inc. | Peptide epoxyketone compounds |
AU2013302269A1 (en) * | 2012-08-14 | 2015-03-12 | Trillium Therapeutics Inc. | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors |
CA2881986A1 (en) * | 2012-08-21 | 2014-02-27 | Fluorinov Pharma Inc. | Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors |
JP6486826B2 (ja) | 2012-10-01 | 2019-03-20 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用 |
AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
SG11201507106PA (en) | 2013-03-14 | 2015-10-29 | Onyx Therapeutics Inc | Dipeptide and tripeptide epoxy ketone protease inhibitors |
WO2014172627A1 (en) | 2013-04-19 | 2014-10-23 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
CN105517998A (zh) * | 2013-09-06 | 2016-04-20 | 桑多斯股份公司 | 通过曼尼希反应立体选择性合成二醇和三醇以及它们在卡非佐米合成中的用途 |
CA2949517A1 (en) | 2014-05-20 | 2015-11-26 | Millennium Pharmaceuticals, Inc. | Boron-containing proteasome inhibitors for use after primary cancer therapy |
EP3808349B1 (de) | 2014-08-07 | 2022-10-05 | Mayo Foundation for Medical Education and Research | Verbindungen und verfahren zur behandlung von krebs |
CN104230857A (zh) * | 2014-08-19 | 2014-12-24 | 上海皓元生物医药科技有限公司 | 卡非佐米(Carfilzomib)的中间体化合物的制备方法及其中间体化合物 |
HUE063851T2 (hu) | 2014-08-22 | 2024-02-28 | Cydex Pharmaceuticals Inc | Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására |
WO2016069479A1 (en) | 2014-10-27 | 2016-05-06 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
US11833122B2 (en) | 2015-11-17 | 2023-12-05 | Calgent Biotechnology Co., Ltd. | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases |
WO2018160717A1 (en) | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
CN106946981B (zh) * | 2017-03-08 | 2020-08-21 | 南京陵瑞医药科技有限公司 | 一种四肽环氧丙烷衍生物及其制备方法和用途 |
US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
WO2019213386A1 (en) * | 2018-05-04 | 2019-11-07 | New Mexico Tech University Research Park Corporation | Proteasome inhibitors |
CN110092813B (zh) * | 2019-06-05 | 2021-05-11 | 南京师范大学 | 一种三肽环氧丙烷衍生物及其制备方法和用途 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5441944A (en) | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US4990448A (en) * | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
JPH05506777A (ja) | 1990-03-05 | 1993-10-07 | セファロン、インコーポレーテッド | キモトリプシン様プロテアーゼ及びそれらの阻害剤 |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
GB9300048D0 (en) | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
JPH0912595A (ja) * | 1995-04-27 | 1997-01-14 | Takeda Chem Ind Ltd | Tan−2178またはその誘導体、その製造法および用途 |
AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
US5834487A (en) * | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
EP1136498A1 (de) | 1996-10-18 | 2001-09-26 | Vertex Pharmaceuticals Incorporated | Inhibitoren von serinproteasen, insbesondere von NS3-protease des hepatitis-c-virus |
NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
AU750207B2 (en) | 1997-06-13 | 2002-07-11 | Cydex Pharmaceuticals, Inc. | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
JPH11124397A (ja) * | 1997-10-21 | 1999-05-11 | Sumitomo Pharmaceut Co Ltd | プロテアソーム阻害剤 |
US6099851A (en) | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
WO2000023614A1 (en) | 1998-10-20 | 2000-04-27 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
WO2001028579A2 (en) * | 1999-10-20 | 2001-04-26 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
JP4412586B2 (ja) | 2002-01-08 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 |
EP1496916A2 (de) | 2002-04-09 | 2005-01-19 | Greenville Hospital System | Metastasen-modulierende wirkung von hochsulfierten oligosacchariden |
US20030224469A1 (en) | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
PL1745064T3 (pl) | 2004-04-15 | 2011-06-30 | Onyx Therapeutics Inc | Związki do hamowania enzymu proteazomu |
AU2005243140A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
CA2565407A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Compounds for enzyme inhibition |
US20060088471A1 (en) * | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Compounds for enzyme inhibition |
PT2260835E (pt) | 2004-12-07 | 2013-05-28 | Onyx Therapeutics Inc | Composição para inibição do proteassoma |
WO2006099261A2 (en) | 2005-03-11 | 2006-09-21 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
CN105237621A (zh) * | 2005-11-09 | 2016-01-13 | 欧尼斯治疗公司 | 用于酶抑制的化合物 |
AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
MX2008016512A (es) * | 2006-06-19 | 2009-02-26 | Proteolix Inc | Epoxicetonas peptidicas para la inhibicion del proteasoma. |
JP4325683B2 (ja) * | 2007-02-14 | 2009-09-02 | セイコーエプソン株式会社 | 画像表示装置、及び画像表示装置の制御方法 |
WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
CL2008002966A1 (es) | 2007-10-04 | 2010-06-25 | Onyx Therapeutics Inc | Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros. |
-
2005
- 2005-05-09 CA CA002565407A patent/CA2565407A1/en not_active Abandoned
- 2005-05-09 AU AU2005243168A patent/AU2005243168B2/en not_active Ceased
- 2005-05-09 RU RU2006143664/04A patent/RU2384585C2/ru not_active IP Right Cessation
- 2005-05-09 SG SG2012082004A patent/SG185963A1/en unknown
- 2005-05-09 SI SI200531893T patent/SI2030981T1/sl unknown
- 2005-05-09 EP EP12189466.1A patent/EP2564834A3/de not_active Withdrawn
- 2005-05-09 BR BRPI0510802-0A patent/BRPI0510802A/pt not_active Application Discontinuation
- 2005-05-09 ES ES08164241.5T patent/ES2510840T3/es active Active
- 2005-05-09 PL PL08164241T patent/PL2030981T3/pl unknown
- 2005-05-09 DK DK08164241.5T patent/DK2030981T3/da active
- 2005-05-09 JP JP2007513279A patent/JP5108509B2/ja not_active Expired - Fee Related
- 2005-05-09 EP EP05742187A patent/EP1758921A2/de not_active Withdrawn
- 2005-05-09 PT PT81642415T patent/PT2030981E/pt unknown
- 2005-05-09 CN CN2012103610166A patent/CN102875642A/zh active Pending
- 2005-05-09 CN CN200580022615.3A patent/CN101014612B/zh not_active Expired - Fee Related
- 2005-05-09 WO PCT/US2005/016335 patent/WO2005111008A2/en active Application Filing
- 2005-05-09 US US11/596,028 patent/US8088741B2/en not_active Expired - Fee Related
- 2005-05-09 EP EP08164241.5A patent/EP2030981B1/de active Active
-
2006
- 2006-11-02 IL IL179020A patent/IL179020A/en active IP Right Review Request
-
2007
- 2007-09-07 HK HK09107615.1A patent/HK1127618A1/xx not_active IP Right Cessation
-
2011
- 2011-08-22 IL IL214776A patent/IL214776A/en active IP Right Grant
- 2011-12-30 US US13/341,056 patent/US20120101026A1/en not_active Abandoned
- 2011-12-30 US US13/341,022 patent/US20120101025A1/en not_active Abandoned
-
2012
- 2012-01-26 JP JP2012013983A patent/JP2012121895A/ja active Pending
- 2012-12-10 IL IL223546A patent/IL223546A0/en unknown
-
2013
- 2013-11-27 JP JP2013245167A patent/JP2014141456A/ja active Pending
-
2014
- 2014-10-07 CY CY20141100803T patent/CY1115605T1/el unknown
-
2016
- 2016-06-09 IL IL246171A patent/IL246171B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2030981E (pt) | Compostos para inibição da enzima proteassoma | |
HK1220208A1 (zh) | 用於酶抑制的化合物 | |
CY2016009I1 (el) | Ενωσεις για την αναστολη του ενζυμου πρωτεασωματος | |
SG152239A1 (en) | Compounds for proteasome enzyme inhibition | |
IL183938A0 (en) | Amino - imidazolones for the inhibition of ?? - becretase | |
IL179398A0 (en) | Dpp-ib inhibitors | |
EP1739418A4 (de) | Substrat für ein labo-on-a-chip | |
PL1716099T3 (pl) | Haloalkilokarboksamidy do zwalczania mikroorganizmów | |
IL181969A0 (en) | Dna-pk inhibitors | |
EP1767204A4 (de) | Lipase-inhibitoren | |
SI1745064T1 (sl) | Spojine za inhibiranje proteasomskega encima | |
GB0421355D0 (en) | Inhibitors | |
HU0400305D0 (en) | Set for spine-fixture | |
GB2411526B (en) | Water-safe cover for ceiling-rose | |
GB0421356D0 (en) | Inhibitors | |
SI2260835T1 (sl) | Sestavek za inhibiranje proteasoma | |
SI1948678T1 (sl) | Spojine za inhibiranje encimov | |
GB0417408D0 (en) | Enzyme inhibitors | |
GB0410302D0 (en) | Enzyme inhibitors | |
GB0428024D0 (en) | Enzyme inhibitors | |
PL114723U1 (en) | Roof-timber for rectangular lining | |
HU0400020V0 (en) | Case for cigarette-packet | |
GB0408300D0 (en) | Novel inhibitors | |
GB0526169D0 (en) | Enzyme inhibitors | |
HU0402636D0 (en) | Serum for soil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200509 |